| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -166,555 | -194,635 | -538,303 | NaN |
| Stock-based compensation | 33,242 | 34,639 | 98,385 | NaN |
| Net loss from equity method investments | -18,283 | -21,029 | -51,579 | NaN |
| Noncash interest expense on deferred royalty obligations | 39,873 | 38,678 | 86,460 | NaN |
| Change in fair value of the embedded derivative associated with the deferred royalty obligation | 2,158 | 8,590 | 11,062 | NaN |
| Noncash income from equity method investments | NaN | 1,064 | 7,769 | NaN |
| Amortization of debt discount and issuance costs | 1,819 | 1,452 | 4,515 | NaN |
| Gain on deconsolidation of subsidiaries | NaN | NaN | 0 | NaN |
| (gain) loss on deconsolidation of subsidiaries | NaN | 0 | NaN | NaN |
| Depreciation and amortization | 1,186 | 1,435 | 3,999 | NaN |
| Gain from investment in equity securities, net | NaN | 0 | 0 | NaN |
| Noncash lease expense | 1,466 | 1,459 | 3,443 | NaN |
| Accrual of payment-in-kind interest on term loan | NaN | 0 | NaN | NaN |
| Loss on extinguishment of debt | 0 | 0 | -21,155 | NaN |
| Other noncash adjustments, net | -306 | 434 | 1,217 | NaN |
| Accounts receivable, net | 65,782 | 22,926 | 111,796 | NaN |
| Inventories | 7,053 | 1,951 | 23,356 | NaN |
| Prepaid expenses and other current assets | 18,845 | -8,750 | 17,527 | NaN |
| Other assets | 1,795 | -545 | -568 | NaN |
| Accounts payable | -7,170 | 17,525 | 9,084 | NaN |
| Accrued compensation and benefits | -37,476 | 19,810 | 3,212 | NaN |
| Accrued research and development liabilities | 12,994 | 6,816 | 347 | NaN |
| Operating lease liabilities | -1,852 | -1,790 | -4,757 | NaN |
| Deferred revenue | -2,379 | -1,948 | -9,480 | NaN |
| Other liabilities | 4,617 | 24,780 | 53,030 | NaN |
| Net cash used in operating activities | -197,279 | -56,420 | -389,490 | NaN |
| Purchases of marketable securities | 52,666 | 17,321 | 10,876 | NaN |
| Maturities of marketable securities | 10,000 | 3,000 | 8,000 | NaN |
| Purchases of investments in equity securities | NaN | 0 | 0 | NaN |
| Proceeds from sales of investments in equity securities | NaN | 0 | 0 | NaN |
| Proceeds from special cash dividends received from an investment in equity securities | NaN | 0 | 2,302 | NaN |
| Payment for an intangible asset | 0 | 0 | 8,495 | NaN |
| Purchases of property and equipment | 69 | 33 | 1,064 | NaN |
| Decrease in cash and cash equivalents resulting from deconsolidation of subsidiaries | NaN | 0 | 0 | NaN |
| Net cash used in investing activities | -42,735 | -14,354 | -10,133 | NaN |
| Proceeds from issuance of 2033 notes /2031 notes-A2033Convertible Senior Notes | 632,500 | NaN | NaN | NaN |
| Issuance costs and discounts associated with 2033 notes/2031 notes-A2033Convertible Senior Notes | 12,796 | NaN | NaN | NaN |
| Proceeds from issuance of 2033 notes /2031 notes-A2031Convertible Senior Notes | 0 | 0 | 575,000 | NaN |
| Issuance costs and discounts associated with 2033 notes/2031 notes-A2031Convertible Senior Notes | 0 | 0 | 12,034 | NaN |
| Repurchase of common stock | 82,500 | 0 | 48,276 | NaN |
| Proceeds from royalty obligation-Royalty Interest Purchase And Sale Agreement | NaN | 300,000 | NaN | NaN |
| Issuance costs and discounts associated with a royalty obligation-Royalty Interest Purchase And Sale Agreement | NaN | 3,010 | NaN | NaN |
| Proceeds from a royalty obligation under the royalty purchase agreement | NaN | NaN | 300,000 | NaN |
| Proceeds from royalty obligation-Funding Agreement | NaN | 0 | NaN | NaN |
| Issuance costs associated with a royalty obligation under the royalty purchase agreement | NaN | NaN | 3,010 | NaN |
| Issuance costs and discounts associated with a royalty obligation-Funding Agreement | NaN | 0 | NaN | NaN |
| Proceeds from term loan under the amended financing agreement-Financing Agreement | NaN | 0 | 0 | NaN |
| Issuance costs and discounts associated with 2031 notes/ issuance costs and discounts associated with term loan under amended financing agreement-Financing Agreement | NaN | 0 | 0 | NaN |
| Repayment of term loans | 0 | 0 | 459,000 | NaN |
| Repayments of deferred royalty obligations | 11,293 | 8,564 | 6,896 | NaN |
| Proceeds from issuance of common stock through public offerings, net | NaN | 0 | 0 | NaN |
| Proceeds from common stock issuances under espp | 5,466 | 0 | 6,414 | NaN |
| Proceeds from stock option exercises, net of repurchases | 22,589 | 13,212 | 14,523 | NaN |
| Transactions with noncontrolling interests | 0 | 600 | 1,550 | NaN |
| Repurchase of rsu shares to satisfy tax withholding | 4,074 | 7,430 | 6,796 | NaN |
| Restricted cash, noncurrent | NaN | NaN | NaN | 1,698 |
| Net cash provided by financing activities | 549,892 | -2,182 | 361,475 | NaN |
| Restricted cash, current | NaN | NaN | NaN | 449 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 309,878 | -72,956 | -38,148 | NaN |
| Cash and cash equivalents, at carrying value, ending balance | NaN | NaN | NaN | 748,953 |
| Cash, cash equivalents, and restricted cash at beginning of period | 572,140 | 645,096 | 683,244 | NaN |
| Cash, cash equivalents, restricted cash, and restricted cash equivalents | NaN | NaN | NaN | 751,100 |
| Cash, cash equivalents, and restricted cash at end of period | 882,018 | 572,140 | 645,096 | NaN |
BridgeBio Pharma, Inc. (BBIO)
BridgeBio Pharma, Inc. (BBIO)